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Accumulating data suggest a potential for substantial overlap in phenotypic and functional charac-
teristics between natural killer and dendritic cells. Thus, their identification, lineage commitment, and
in vivo relevance may need a closer look.Natural killer (NK) cells and dendritic
cells (DCs) are well-recognized, impor-
tant constituents of the innate immune
system. Based on historical prece-
dent, NK cells have been relegated to
the job of killing virus-infected cells
and tumors and secreting interferon-g
when activated (Hamerman et al.,
2005; Lanier, 2005), whereas DCs
have gained prominence based on
their abilities to uptake, process, and
present antigens to T cells and pro-
duce cytokines that influence the in-
nate and adaptive immune responses
(Banchereau et al., 2000; Mellman
and Steinman, 2001). However, if one
considers the cell-surface phenotype,
functions, and developmental relation-
ship of these cell types, they share
many common properties that are of-
ten overlooked. In particular, compari-
son of mouse and human NK cells and
DCs suggests that these cell types
may be highly related and in some cir-
cumstances or activation states may
serve overlapping functions. A reevalu-
ation of what is known about these
cells indicates that killing is not the ex-
clusive domain of NK cells, nor is anti-
genpresentation necessarily restricted
to DCs. The recent description in mice
of an interferon-producing killer den-
dritic cell (IKDC) (Chan et al., 2006;
Taieb et al., 2006), as well as other
reports of DCs with cytolytic activity
(Homann et al., 2002; Josien et al.,
1997; Pillarisetty et al., 2005; Trinite
et al., 2000), further blurs the distinc-
tion between NK cells and DCs.
DC Subsets
Subsets of DCs in mice and humans
have been defined based on their
cell-surface phenotype and functionalproperties. These include conven-
tional DCs, which comprise a number
of different subsets based on their
cell-surface phenotype (Banchereau
et al., 2000), and ‘‘plasmacytoid’’ DCs
(also referred to as interferon-produc-
ing cells) (Liu, 2005), as well as imma-
ture, mature, and activated forms of
these cell types. For simplicity, we
will refer to these as conventional (c)
DCs and plasmacytoid (p) DCs.
In humans, the cDCs and pDCs are
functionally distinguished by their abil-
ity to produce distinct cytokines and
interferons (reviewed in Banchereau
et al., 2000; Liu, 2005). Specifically,
after stimulation by CpG oligonucleo-
tides or viruses, pDCs secrete abun-
dant amounts of type I interferons,
whereas cDCs produce more modest
amounts of type I interferon. Recipro-
cally, cDCs predominantly secrete
IL-12 in response to activation through
several Toll-like receptors (TLRs) that,
in turn, induces the production of inter-
feron-g (IFN-g) by NK cells and T cells.
Immature cDCs are considered the
most efficient cells for antigen uptake,
and as they mature, they process
these antigens and stably express
these peptides on their cell-surface
MHC molecules for presentation to
T cells. MHC class II on the DCs is re-
quired for presentation of peptides to
CD4+ T cells, and activation of the
T cell is enhanced by costimulatory
molecules on the DCs (such as CD80
and CD86 that interact with CD28 on
T cells, OX40 ligand (OX40L) on DCs
engaging OX40 on T cells, and CD40
on the DCs) that further activates the
DCs after contact with CD40 ligand
on the activated T cells (Banchereau
et al., 2000).ImmunityHuman cDCs and pDCs can be
identified and isolated based on their
preferential expression of certain cell-
surface markers (Table 1). In particu-
lar, cDCs express high amounts of
CD11b (the aM, b2 integrin commonly
referred to a Mac-1) and CD11c (the
ax, b2 integrin) on their cell surface,
whereas pDCs do not express sub-
stantial amounts of these proteins,
but do uniquely express blood den-
dritic cell antigen 2 (BDCA2) and ILT7
(CD85g). Human cDCs and pDCs lack
expression of cell-surface receptors
typically expressed on NK cells, in-
cluding CD56, killer cell immunoglobu-
lin-like receptor (KIR), and CD161.
Mice possess cDCand pDCsubsets
also characterized by predominant
IL-12 versus type I interferon produc-
tion, respectively. Mouse cDCs have
been reported to secrete IFN-g under
some circumstances, but in amounts
much lower than produced by NK cells
or T cells (Vremec et al., 2006). cDCs
and pDCs both express MHC class II,
CD80, CD86, CD40, and OX40L;
thus, they are both capable of antigen
presentation to T cells, with cDCs con-
sidered the most efficient at this activ-
ity. Unlike human pDCs that lack
CD11c, mouse pDCs express CD11c
and also express B220, an isoform of
CD45 first characterized as a marker
for mouse B cells. Orthologs of human
ILT7 and BDCA2 have not been identi-
fied in mice; however, mouse pDCs
uniquely express plasmacytoid den-
dritic cell antigen-1 (PDCA1) and
Siglec H. cDCs and pDCs do not ex-
press the NK cell-associated markers
NK1.1, NKG2D, CD49b, or Ly49.
Murine cells expressing markers
shared by both DCs and NK cells26, January 2007 ª2007 Elsevier Inc. 11
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IFN-g no or low no yes
IFN-a/b low high no or low
IL-12 high no or low no
APC yes yes yes (activated)
(Hanna et al., 2004;
Roncarolo et al., 1991;
Zingoni et al., 2004)
Antigenic Phenotype
MHC class II yes yes yes (activated)
(Hanna et al., 2004;
Roncarolo et al., 1991;
Zingoni et al., 2004)
CD80 + CD86 yes yes (activated) yes (activated)
(Hanna et al., 2004;
Zingoni et al., 2004)
CD40 yes yes no
OX40 ligand yes yes yes (activated)
(Hanna et al., 2004;
Zingoni et al., 2004)
CD11b yes no yes
(Ault and Springer, 1981;
Nagler et al., 1989)
CD11c yes no yes (Nagler et al., 1989)
BDCA2 no yes no
ILT7 no yes (Cao et al., 2006) no (Cao et al., 2006)
KIR no no yes
CD56 no no yes
CD161 no no yeshave been reported by several investi-
gators (Chan et al., 2006; Homann
et al., 2002; Josien et al., 1997; Pillari-
setty et al., 2005; Taieb et al., 2006;
Trinite et al., 2000; Vremec et al.,
2006). In particular, a population of
mouse cells coexpressing markers
shared by DCs and NK cells has
been designated as an interferon-pro-
ducing killer dendritic cell (IKDC) (Chan
et al., 2006; Taieb et al., 2006). Proper-
ties of these cells are summarized in
Table 2. IKDCs are present at low fre-
quencies in spleen and lymph nodes
(Chan et al., 2006) as well as infiltrating
tumors (Taieb et al., 2006). These cells
demonstrated cell-mediated cytotox-
icity through the activating Ly49H and12 Immunity 26, January 2007 ª2007 ElsNKG2D NK receptors (Chan et al.,
2006) and caused TRAIL-dependent
elimination of B16F10 tumors (Taieb
et al., 2006). IKDCs isolated from the
lymph nodes, but not the spleen,
demonstrated efficient antigen pre-
sentation to T cells in vivo and in vitro,
and this activity correlated with the
higher amounts of MHC class II and
CD86 on IKDC in lymph nodes. In ad-
dition to their lytic activity, activated
IKDCs secrete IFN-g and modest
amounts of type I interferon (Chan
et al., 2006; Taieb et al., 2006; Vre-
mec et al., 2006), although other stud-
ies have not detected type I interferon
production by IKDCs (Vremec et al.,
2006).evier Inc.Antigen Presentation by Human
NK Cells
Although for aficionados of the mouse
immune system a cell coexpressing
MHC class II and NK receptors and
mediating both cytolytic activity and
antigen-presenting cell (APC) function
may have been unexpected, students
of the human immune system were
not caught unawares. A most notable
difference between mouse and human
NK cells is the expression of MHC
class II proteins on activated human
NK cells (Phillips et al., 1984). Whereas
in mice IKDCs comprise a rather small
subset of cells, all activated human NK
cells express HLA-DR. In addition,
activated human NK cells express
a number of costimulatory molecules,
including CD80, CD86, OX40L, and
CD70 (Table 1; Hanna et al., 2004; Zin-
goni et al., 2004). MHC class II and
these costimulatory ligands are ex-
pressed not only by in vitro activated
human NK cells but also by NK cells
isolated from inflamed tonsils (Hanna
et al., 2004), indicating that the induc-
tion of thesemolecules is not an in vitro
curiosity. Three independent laborato-
ries have established that activated
human NK cells are able to process
and present antigens, thus enabling
them to activate CD4+ T cells (Table
1; Hanna et al., 2004; Roncarolo
et al., 1991; Zingoni et al., 2004). Ron-
carolo et al. reported that activated
freshly isolated NK cells and cloned
lines of humanNK cells are able to pro-
cess protein antigens (tetanus toxoid
and the house dust mite antigen Der
p1) and present these peptides on
HLA-DR to antigen-specific CD4+ T
cells (Roncarolo et al., 1991). Both
CD56+, CD16 and CD56+, CD16++
NK cells were able to function as
APCs (Roncarolo et al., 1991). Al-
though contamination of the freshly
isolated NK cell population with a small
number of DCs may have confounded
the interpretation that freshly activated
NK cells present antigen, the observa-
tion that long-term cloned NK cell lines
obtained from freshly isolated NK cells
effectively presented antigen makes
it very unlikely that contamination of
the NK cell preparations by DCs was
responsible for the observed APC ac-
tivities (Roncarolo et al., 1991). How-
ever, not all proteins were processed
Immunity
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(Chan et al., 2006;
Taieb et al., 2006;
Vremec et al., 2006)
yes
IFN-g low or no
(Vremec et al., 2006)
no yes
(Chan et al., 2006;
Taieb et al., 2006;
Vremec et al., 2006)
yes
IFN-a/b low or no high low (Chan et al., 2006) no or low
IL-12 high low yes (Chan et al., 2006) no
APC yes yes yes, LN; no, spleen
(Chan et al., 2006)
no
Antigenic Phenotype
MHC class II yes yes yes
(higher on LN than spleen)
(Chan et al., 2006;
Taieb et al., 2006)
no (Chan et al., 2006)
CD80 + CD86 yes yes yes, LN; no, spleen
(Chan et al., 2006)
no (Chan et al., 2006)
CD40 yes yes yes, LN; no, spleen
(Chan et al., 2006)
no (Chan et al., 2006)
OX40 ligand yes yes ? no
(K. Takeda, personal
communication)
CD11b yes no yes
(Chan et al., 2006;
Taieb et al., 2006;
Vremec et al., 2006)
yes
(Lanier et al., 1986;
Puzanov et al., 1996)
CD11c yes yes yes
(Chan et al., 2006;
Taieb et al., 2006;
Vremec et al., 2006)
yes
(Laouar et al., 2005;
Schleicher et al., 2005)
B220 no yes yes
(Chan et al., 2006;
Taieb et al., 2006;
Vremec et al., 2006)
yes
(Puzanov et al., 1996)
Siglec H no
(Blasius et al., 2006)
yes
(Blasius et al., 2006)
? no
(Blasius et al., 2006)
PDCA1 no yes no (Chan et al., 2006) no (Chan et al., 2006)
NK1.1 no no yes
(Chan et al., 2006;
Taieb et al., 2006)
yes
Ly49a no no yes (Chan et al., 2006) yes
NKG2D no no yes
(Chan et al., 2006;
Taieb et al., 2006)
yes
CD49b (DX5) no no yes
(Chan et al., 2006;
Taieb et al., 2006;
Vremec et al., 2006)
yes
a Excluding Ly49QImmunity 26, January 2007 ª2007 Elsevier Inc. 13
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shock protein from Mycobacterium
leprae was not processed, although
a peptide derived from this protein
was presented effectively by NK cells
to M. leprae-specific CD4+ T cells
(Roncarolo et al., 1991). Hanna et al.
confirmed and extended these obser-
vations by showing that human NK
cells that were cocultured with influ-
enza-infected target cells upregulated
CD86 and MHC class II and presented
antigens acquired from the lysed tar-
gets to influenza-specific CD4+ T cells
(Hanna et al., 2004). By contrast, NK
cells killing target cells not infected
by influenza virus were unable to acti-
vate influenza-specific T cells (Hanna
et al., 2004). These findings, together
with the observation that antigen-
pulsed activated NK cells can stimu-
late naive T cells, strongly suggest
that NK cells killing virus-infected cells,
and probably also tumor cells, can
initiate an antigen-specific adaptive
immunity in vivo. The APC activity
mediated by NK cells is moderately
inhibited by soluble CTLA-4 fusion
protein, which binds to CD80 and
CD86 (Hanna et al., 2004). Similarly,
Zingoni et al. demonstrated that the
activation of naive CD4+ T cells by
superantigen presented by activated
NK cells was partially prevented by in-
dividually blocking CD80 or CD86, or
more potently inhibited by blocking
OX40L expressed on activated human
NK cells; a combination of antibodies
against these three costimulatory li-
gands on NK cells completely inhib-
ited antigen-specific T cell stimulation
by activated NK cells (Zingoni et al.,
2004). It is interesting to note that
OX40L has been shown to inactivate
IL-10-producing regulatory T cells
(Tr1), suggesting the possibility that
NK cells when lysing virus-infected
cells may influence the adaptive im-
mune response by stimulating CD4+
effector T cells and inactivating Tr1-
mediated suppression (Ito et al.,
2006). Prevailing evidence suggests
that DCs are the predominant media-
tors of APC function in vivo; however,
the recent appreciation that NK cells
are present in human lymph nodes in
proximity to naive T cells (Fehniger
et al., 2003) suggests the possibility
that in some circumstances, NK cells14 Immunity 26, January 2007 ª2007 Elshave the opportunity to present anti-
gen, and it has been demonstrated in
vitro that they have all the molecules
and mechanisms necessary to do so.
Issues to Consider in Identifying
DCs, IKDCs, and NK Cells
Cell types in the immune system are
usually identified and isolated for func-
tional studies based on the expression
of cell-surface molecules visualized
by staining with fluorochrome-conju-
gated monoclonal antibodies and
flow cytometric analysis. With few
exceptions, such as the T cell antigen
receptor on T cells and surface immu-
noglobulin on B cells, most of these
cell-surface antigens are expressed
onseveral cell types. This is particularly
true for many of themarkers frequently
used to identify DC subsets. For
example, CD11c is often considered
a marker for cDCs in humans and
pDCs in mice; however, CD11c is ex-
pressed by both human and mouse
NK cells (Tables 1 and 2). Similarly, al-
though often considered a ‘‘myeloid’’
marker, CD11b is expressed not only
on mouse and human cDCs but is
also present on mouse and human
NK cells, as well as on some antigen-
specificCD8+ cytotoxic T lymphocytes
(McFarland et al., 1992). Inmice, B220,
once considered a prototypical ‘‘B cell
marker,’’ not only is present on mouse
pDCs and IKDCs but is also expressed
in low amounts on resting mouse NK
cells and is highly upregulated after
NK cell activation. The ‘‘pan-NK’’
monoclonal antibody DX5 recognizes
CD49b, an integrin also present on
some activated T cells, basophils,
platelets, endothelial cells, fibroblasts,
and epithelial cells. NKG2D is ex-
pressed on essentially all NK cells
but is downregulated after exposure
to ligand-bearing cells; moreover, in
some circumstances, we have ob-
served the apparent expression of
NKG2D on myeloid cells, making it
unsuitable for unambiguously distin-
guishing NK cells and DCs (Y. Zhu
and L.L.L., unpublished observations).
Often, cell types are identified not on
the presence or absence of a particular
cell-surface molecule, but on the rela-
tive amount of expression of the
marker, with designations such as
‘‘low’’ or ‘‘high.’’ An unappreciatedevier Inc.complication is that depending on the
efficiency of the fluorochrome conju-
gated to the particular monoclonal
antibody and the amount of compen-
sation necessary to discriminate be-
tween different fluorochromes, what
may appear ‘‘negative’’ with one re-
agent or instrument may be scored as
‘‘low’’ with other detection methods.
These potential problems needs to be
taken into consideration when design-
ing experiments to evaluate the func-
tion ofNKcells orDCsubsets, because
even a minor contamination with a
functionally potent cell population
might lead to inappropriate conclu-
sions about the cell type mediating
the activity. With respect to mouse
IKDCs, perhaps the only unambiguous
identification of this cell type is coex-
pression of NK1.1 and MHC class II
on cells from C57BL/6 mice. Unfortu-
nately, NK1.1 is an alloantigen and is
not expressed in many commonly
used mouse strains, such as BALB/c.
Although DX5 (CD49b) is commonly
used as a ‘‘pan-NK marker’’ in mouse
strains lacking NK1.1, the caveats of
using CD49b were described above.
For non-C57BL6 mouse strains, pres-
ently themost unambiguous identifica-
tion of IKDCs would be by the demon-
stration of coexpression of MHC class
II and the appropriate Ly49 receptors
(e.g., inC57BL/6 andBALB/cmice, ex-
pression of Ly49A and Ly49G2, and in
C57BL/6, mice expression of Ly49D).
DefiningCell Lineages—NKCells
and DCs
Ultimately, all hematopoietic cells
arise from a common stem cell; how-
ever, progenitor cells with more re-
stricted capacity for differentiation
into different cell types emerge, with
cell lineages being defined by com-
mon gene expression and cellular
functions. Prior studies in mice have
indicated that NK cells emerge from
lymphoid but not frommyeloid precur-
sors in vivo (Akashi et al., 2000; Kondo
et al., 1997). Additionally, in humans,
NK cells are developmentally related
to lymphocytes, in particular to T cells
(Blom and Spits, 2006). Other studies,
both in mouse and human, have dem-
onstrated that certain cDC and pDC
populations can develop from either
common myeloid or lymphoid
Immunity
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derived from a ‘‘common lymphoid
progenitor’’ (CLP) (Blom and Spits,
2006; Chicha et al., 2004; Shigematsu
et al., 2004). Therefore, these findings
suggest that some types of DCs may
share a common developmental path-
way with NK cells. A recent study pro-
vides evidence for a lymphoid origin of
IKDCs, although NK cells and IKDCs
may derive from different subsets of
lymphoid precursors (P. Kincade, per-
sonal communication).
A defining requirement for the effi-
cient development of mature NK cells
is the ability to signal through the
IL-15 receptor complex. It is well es-
tablished that mice with deficiencies
in IL-15, the IL-2 and IL-15 receptor g
common (gc) subunit, the IL-2Rb sub-
unit, the IL-15Ra chain, or Jak3 have
greatly reduced numbers of NK cells
(Di Santo, 2006). Similarly, human gc-
deficient X chromosome-linked severe
immunodeficiency patients lack NK
cells (Leonard, 1996). cDCs and
pDCs are present in relatively normal
abundance in mice lacking IL-2Rb
(Chan et al., 2006), indicating that the
IL-15R complex is not required for
development of these cells.
With respect to the mouse IKDCs,
Chan et al. reported that IL-2Rb-defi-
cient mice lack IKDCs (Chan et al.,
2006), and our recent studies indicate
that IKDCs are less abundant in mice
lacking IL-15 or IL-15Ra chain (Y. Zhu
and L.L.L., unpublished observation).
In this respect, IKDCs are similar to
NK cells. Surprisingly, Taieb et al. re-
ported that gc-deficient mice contain
IKDCs based on detection of cells ex-
pressing CD49b, B220, and CD11c
(Taieb et al., 2006); however, neither
the expression of MHC class II or
more NK cell-specific markers nor
the functional capacity of these cells
to mediate cytotoxicity or present anti-
gen were evaluated.
Cell fates are governed by trans-
cription factors and analysis of mice
deficient for these factors provides in-
formation about the developmental
relationship of cell types. The tran-
scriptional inhibitor Id2, which antago-
nizes transcription factors of the E pro-
tein subfamily of the basic helix loop
helix factors, is required for the de-
velopment of NK cells (Yokota et al.,1999) and IKDCs, whereas pDCs are
present in normal abundance in Id2-
deficient mice (P. Kincade, personal
communication). Thus, the limited
studies with gene-modified mice point
to a much closer relationship of IKDCs
with NK cells than with DCs.
Conclusions and Speculation
Further studies will be necessary to
conclusively establish the relationship
between NK cells, DCs, and IKDCs.
Mouse IKDCs appear to have more in
common with NK cells, in particular
with human NK cells, than with other
populations of DCs. The ability of the
mouse IKDCs to ‘‘convert’’ from cells
with NK cell lytic activity and expres-
sion of NK receptors into cells acquir-
ing MHC class II and the requisite
molecules for APC function is quite
reminiscent of human NK cells. If one
considers the dramatic alterations
forced upon NK cells to switch from
Ly49 receptor-dominated recognition
mechanisms in mice to the KIR system
in primates, it is possible that a subset
of NK cells in mice with the capacity to
express MHC class II and mediate
APC function represents the transi-
tional population that gave rise to NK
cells in primates. Although specula-
tive, an intriguing possibility is that
the IKDCs in mice may represent the
evolutionary progenitor of the emerg-
ing predominant population of NK cells
in humans endowed with APC
function.
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